On December 28, 2012, the FDA granted approval to a new drug from Bristol-Myers Squibb, a move that may broaden the company's portfolio and influence competitive dynamics in the pharmaceutical market.
On December 28, 2012, the FDA granted approval to a new drug from Bristol-Myers Squibb, a move that may broaden the company's portfolio and influence competitive dynamics in the pharmaceutical market.